TheraCryf plc Reports Significant Progress in Drug Development Programs

Evgen Pharma ( (GB:TCF) ) has issued an announcement.

TheraCryf plc announced progress in its lead asset Ox-1, an orexin 1 antagonist for addictive behaviors, with successful optimization efforts by partner Pharmaron UK to scale up production for clinical studies. The company’s legacy SFX-01 program also shows promising results, with the drug crossing the blood-brain barrier in glioblastoma treatment and demonstrating targeted activity in colorectal cancer models. These developments highlight TheraCryf’s strategic focus on advancing its clinical pipeline and leveraging collaborations to unlock asset value.

Spark’s Take on GB:TCF Stock

According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.

Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.

To see Spark’s full report on GB:TCF stock, click here.

More about Evgen Pharma

TheraCryf plc is a clinical stage drug development company focused on brain disorders, with a diverse pipeline addressing conditions such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data for preclinical and clinical proof of concept, partnering with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is listed on AIM in London under the ticker symbol TCF.

Average Trading Volume: 2,623,556

Technical Sentiment Signal: Sell

Current Market Cap: £5.48M

For detailed information about TCF stock, go to TipRanks’ Stock Analysis page.